GW Pharmaceuticals Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 1.1K
- Market Cap
- -
- Website
- http://gwpharm.com
A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- GW Pharmaceuticals Ltd
- Registration Number
- NCT02432612
A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- GW Pharmaceuticals Ltd
- Registration Number
- NCT02325024
A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects
- First Posted Date
- 2014-09-15
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- GW Pharmaceuticals Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT02240160
A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- GW Pharmaceuticals Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT01975688
- Locations
- 🇬🇧
Quintiles London Drug Research Unit, London, United Kingdom
Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- GW Pharmaceuticals Ltd
- Target Recruit Count
- 397
- Registration Number
- NCT01262651
A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.
Phase 2
Completed
- Conditions
- Palliative CarePainCancer
- Interventions
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- GW Pharmaceuticals Ltd
- Target Recruit Count
- 360
- Registration Number
- NCT00530764
- Locations
- 🇺🇸
A & A Pain Institute of St. Louis, St. Louis, Missouri, United States
🇨🇦Vancouver Health Research Center, Victoria, British Columbia, Canada
🇺🇸Office of Donald H. Berdeaux MD, Great Falls, Montana, United States
Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- GW Pharmaceuticals Ltd
- Target Recruit Count
- 339
- Registration Number
- NCT00391079
- Locations
- 🇨🇦
Dalhousie MS Research Clinic, Halifax, Nova Scotia, Canada
🇨🇦MS Clinic, UBC Purdy Pavilion, Vancouver, British Columbia, Canada
🇨🇦London Health Sciences Centre / University Hospital, London, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath